



PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 45306

Title: Cholestatic liver diseases: An era of emerging therapies

Reviewer's code: 02567646

Reviewer's country: United Kingdom

Science editor: Ying Dou

Reviewer accepted review: 2019-01-14 22:11

Reviewer performed review: 2019-01-18 22:31

Review time: 4 Days

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language	(High priority)	<input checked="" type="checkbox"/> Anonymous
<input checked="" type="checkbox"/> Grade C: Good	polishing	<input checked="" type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of	(General priority)	Peer-reviewer's expertise on the
<input type="checkbox"/> Grade E: Do not	language polishing	<input type="checkbox"/> Minor revision	topic of the manuscript:
publish	<input type="checkbox"/> Grade D: Rejection	<input type="checkbox"/> Major revision	<input checked="" type="checkbox"/> Advanced
		<input type="checkbox"/> Rejection	<input type="checkbox"/> General
			<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

The article is well written and balanced. The diagrams and table are helpful. Minor comments: 1. P7, 3rd paragraph, first line. I would remove the authors name. The format will then be unison. 2. P10, 2nd paragraph, 3rd line - insert the word 'to' after failed.



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

INITIAL REVIEW OF THE MANUSCRIPT

Google Search:

- The same title
- Duplicate publication
- Plagiarism
- No

BPG Search:

- The same title
- Duplicate publication
- Plagiarism
- No



PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 45306

Title: Cholestatic liver diseases: An era of emerging therapies

Reviewer's code: 02447901

Reviewer's country: Taiwan

Science editor: Ying Dou

Reviewer accepted review: 2019-01-21 23:48

Reviewer performed review: 2019-01-22 01:11

Review time: 1 Hour

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input checked="" type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language	(High priority)	<input checked="" type="checkbox"/> Anonymous
<input type="checkbox"/> Grade C: Good	polishing	<input checked="" type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of	(General priority)	Peer-reviewer's expertise on the
<input type="checkbox"/> Grade E: Do not	language polishing	<input type="checkbox"/> Minor revision	topic of the manuscript:
publish	<input type="checkbox"/> Grade D: Rejection	<input type="checkbox"/> Major revision	<input type="checkbox"/> Advanced
		<input type="checkbox"/> Rejection	<input checked="" type="checkbox"/> General
			<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

There was no additional comment.

INITIAL REVIEW OF THE MANUSCRIPT

Google Search:



Baishideng Publishing Group

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

- The same title
- Duplicate publication
- Plagiarism
- No

BPG Search:

- The same title
- Duplicate publication
- Plagiarism
- No



PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 45306

Title: Cholestatic liver diseases: An era of emerging therapies

Reviewer's code: 04870360

Reviewer's country: Egypt

Science editor: Ying Dou

Reviewer accepted review: 2019-01-21 16:04

Reviewer performed review: 2019-01-23 14:04

Review time: 1 Day and 21 Hours

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	<input checked="" type="checkbox"/> Accept	Peer-Review:
<input checked="" type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language	(High priority)	<input checked="" type="checkbox"/> Anonymous
<input type="checkbox"/> Grade C: Good	polishing	<input type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of	(General priority)	Peer-reviewer's expertise on the
<input type="checkbox"/> Grade E: Do not	language polishing	<input type="checkbox"/> Minor revision	topic of the manuscript:
publish	<input type="checkbox"/> Grade D: Rejection	<input type="checkbox"/> Major revision	<input type="checkbox"/> Advanced
		<input type="checkbox"/> Rejection	<input checked="" type="checkbox"/> General
			<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

regarded to the manuscript entitled "Emerging Therapies in Cholestatic Liver Disease" the authors focused their research on advanced and new therapies for cholestatic liver diseases with very good exploration of newly proposed mechanisms involved in this problem. also, they investigated anti-cholestatic therapeutic options of ursodeoxycholic



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

acid (UDCA) and other target nuclear receptors regulating bile acid (farnesoid X receptor (FXR)) and G protein-coupled receptor (TGR5) and fibroblast growth factor-19. this manuscript is well written and its quality is good to published in the World Journal of Gastroenterology. The only comment is grammar mistakes, this manuscript contains a lot of grammar and typos errors so, I encourage authors to revise this manuscript before acceptance.

INITIAL REVIEW OF THE MANUSCRIPT

Google Search:

- The same title
- Duplicate publication
- Plagiarism
- No

BPG Search:

- The same title
- Duplicate publication
- Plagiarism
- No



PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 45306

Title: Cholestatic liver diseases: An era of emerging therapies

Reviewer's code: 03488316

Reviewer's country: Saudi Arabia

Science editor: Ying Dou

Reviewer accepted review: 2019-01-22 13:44

Reviewer performed review: 2019-01-28 10:22

Review time: 5 Days and 20 Hours

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input checked="" type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language	(High priority)	<input checked="" type="checkbox"/> Anonymous
<input type="checkbox"/> Grade C: Good	polishing	<input type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of	(General priority)	Peer-reviewer's expertise on the
<input type="checkbox"/> Grade E: Do not	language polishing	<input type="checkbox"/> Minor revision	topic of the manuscript:
publish	<input type="checkbox"/> Grade D: Rejection	<input checked="" type="checkbox"/> Major revision	<input type="checkbox"/> Advanced
		<input type="checkbox"/> Rejection	<input checked="" type="checkbox"/> General
			<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

Reviewer's Code: 03488316 The article is concerned with significant and interesting scientific problem, as cholestatic liver diseases affect tens of thousands of people each year. Associated with many complication, specially its end-stage sequela of liver fibrosis and cirrhosis which are major causes of morbidity and mortality



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

worldwide. In addition the article contribute towards solving this problem and is novel and innovative. POINTS TO BE ADDRESSED BY THE SPECIFIC COMMENTS FOR THE VARIOUS ARTICLE SECTIONS The overall structure of the manuscript is complete. The scientific question proposed in the manuscript is clearly presented in the introduction section, along with the aim and potential significance of the study. Title: the main and short titles accurately reflect the major topic and content of the study. Abstract: the abstract provide a clear delineation reflecting and improved understanding of chronic cholestatic diseases. Novel anti-cholestatic therapeutic options have evolved for patients not favorably responding to ursodeoxycholic acid (UDCA). Conclusion section: The conclusions of the manuscript are clearly presented in the Conclusion section. References: the references are appropriate, relevant, and up-to-date. Tables and Figures: the tables and/or figures reflect the major findings of the study and designed to present the maximal amount of information in the most concise and clear manner. Peer-reviewers' conclusions The article is concerned with significant and interesting scientific questions. In addition the article contributes towards solving this problem and is novel and innovative. The manuscript have value for publication as they start a new strategy for prevention of cholestatic liver diseases . However another review articles deal with this cholestatic liver diseases in a more details and no novel ideas or drugs added by the authors. 1. The study of Goldstein J1, Levy C2 Novel and emerging therapies for cholestatic liver diseases. Liver Int. 2018 Sep;38(9):1520-1535. doi: 10.1111/liv.13880. Epub 2018 Jun 14. Clarified animal models and human studies elucidating bile acid physiology, their associated nuclear and surface receptors, transporters and role in cholestatic diseases, the emergence of new therapeutic targets for PBC and PSC. In addition to bile acid derivatives and FXR agonists, drugs targeting a variety of other signalling pathways. 2. The study of Santiago P1, Scheinberg AR1, Levy C2. Cholestatic liver diseases: new



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

targets, new therapies. Therap Adv Gastroenterol. 2018 Aug 24;11:1756284818787400. doi: 10.1177/1756284818787400. eCollection 2018. Showed the new promising targets for the treatment of cholestatic liver diseases, with the recent advances in the knowledge of molecular mechanisms implicated in these diseases. Both of the two studies have representative very good illustrative figures of the mechanisms of different approach. CLASSIFICATION OF THE MANUSCRIPT B: Very good LANGUAGE EVALUATION B: Minor language polishing required

INITIAL REVIEW OF THE MANUSCRIPT

Google Search:

- The same title
- Duplicate publication
- Plagiarism
- No

BPG Search:

- The same title
- Duplicate publication
- Plagiarism
- No